BioCardia, Inc. (NASDAQ:BCDA) Sees Large Decrease in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 50,400 shares, a decrease of 39.6% from the December 31st total of 83,400 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 48,500 shares, the days-to-cover ratio is presently 1.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of BioCardia in a report on Wednesday, December 18th.

BioCardia Trading Up 0.4 %

BioCardia stock opened at $2.28 on Wednesday. BioCardia has a 52 week low of $1.63 and a 52 week high of $8.85. The firm’s 50-day simple moving average is $2.19 and its 200 day simple moving average is $2.53.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.